About the Company
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, its mandate is simple yet comprehensive - work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.
Employees
70
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SLDB News
Solid Biosciences (SLDB) Gets a Buy from Barclays
In a report released yesterday, Gena Wang from Barclays assigned a Buy rating to Solid Biosciences (SLDB – Research Report), with a price ...
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million ...
Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4
Stock of Solid Biosciences Inc. (SLDB) is moving down over 4 percent on Wednesday morning following the announcement of an increase ...
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB), a life sciences company developing precision genetic ...
Solid Biosciences Inc SLDB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4
(RTTNews) - Stock of Solid Biosciences Inc. (SLDB) is moving down over 4 percent on Wednesday morning following the announcement of an increase in loss in the fourth-quarter. The company's loss ...
Solid Biosciences Inc SLDB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Solid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 ...
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following ...
Loading the latest forecasts...